| 9.07 0.06 (0.67%) | 06-25 10:29 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.76 | 1-year : | 12.57 |
| Resists | First : | 9.21 | Second : | 10.76 |
| Pivot price | 8.36  |
|||
| Supports | First : | 8.17 | Second : | 7.53 |
| MAs | MA(5) : | 8.88 |
MA(20) : | 8.35 |
| MA(100) : | 8.08 |
MA(250) : | 9.28 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 80.8 |
D(3) : | 81.6 |
| RSI | RSI(14): 58.2 |
|||
| 52-week | High : | 12.73 | Low : | 6.46 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ XLO ] has closed below upper band by 27.8%. Bollinger Bands are 51.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.1 - 9.13 | 9.13 - 9.17 |
| Low: | 8.81 - 8.85 | 8.85 - 8.89 |
| Close: | 8.93 - 9.01 | 9.01 - 9.07 |
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
Thu, 18 Jun 2026
XLO Stock Price, Quote & Chart - ChartMill
Wed, 17 Jun 2026
Xilio Therapeutics Inc (XLO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fri, 12 Jun 2026
Daniel Curran reappointed to Class III director at Xilio - TradingView
Fri, 12 Jun 2026
Xilio Therapeutics (XLO) director receives grant of 5,000 stock options - Stock Titan
Fri, 12 Jun 2026
Xilio Therapeutics (XLO) director receives grant of 5,000 stock options at $7.99 - Stock Titan
Tue, 12 May 2026
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 28.5 (%) |
| Held by Institutions | 53.5 (%) |
| Shares Short | 165 (K) |
| Shares Short P.Month | 163 (K) |
| EPS | -2.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.78 |
| Profit Margin | -58.6 % |
| Operating Margin | -111.6 % |
| Return on Assets (ttm) | -19.8 % |
| Return on Equity (ttm) | -75.2 % |
| Qtrly Rev. Growth | 331.7 % |
| Gross Profit (p.s.) | 8.12 |
| Sales Per Share | 8.12 |
| EBITDA (p.s.) | -6.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -3.85 |
| PEG Ratio | 0 |
| Price to Book value | 1.12 |
| Price to Sales | 1.07 |
| Price to Cash Flow | -1.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|